IRMDNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

iRadimed Corporation

IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service. The company serves hospitals and acute care facilities that need equipment that can operate safely in the magnetic environment of MRI suites.

Liikevaihto83,8milj. USD
+14,4 %v/v
Liikevoitto (EBIT)26,1milj. USD
+19,0 %v/v
EBIT-marginaali31,2%
+1,2 %-yks.v/v
Nettotulos22,5milj. USD
+16,9 %v/v
Vapaa kassavirta17,2milj. USD
−2,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−20020406080100milj. USD2020: 32 milj. USD2020: EBIT −0,76 milj. USD20202021: 42 milj. USD2021: EBIT 9,8 milj. USD20212022: 53 milj. USD2022: EBIT 16 milj. USD20222023: 66 milj. USD2023: EBIT 20 milj. USD20232024: 73 milj. USD2024: EBIT 22 milj. USD20242025: 84 milj. USD2025: EBIT 26 milj. USD20258426
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
MRI-compatible infusion pump systems45 %

Scanner-room infusion pumps and associated tubing sets used to deliver medication during MRI procedures.

MRI-compatible patient monitoring systems27 %

Vital signs monitoring systems designed to function safely in MRI environments.

Disposables21 %

Single-use tubing and related consumables sold with installed devices and recurring usage.

Service and maintenance7 %

Extended maintenance agreements, service work, and other support tied to installed equipment.

Asiakkaat

IRADIMED sells primarily to hospitals and acute care facilities with MRI equipment on site, where clinical staff need infusion and monitoring tools that are safe in the scanner room. In the U.S., the company sells largely to end users, while internationally it relies more on distributors, which affects pricing, support, and customer access.

Hospitals with MRI suites

Buy infusion pumps, monitors, and disposables for safe use during MRI procedures and to improve workflow.

Acute care facilities

Purchase MRI-compatible devices for critical-care imaging environments where patient monitoring is essential.

International distributors

Buy products for resale outside the U.S., extending market reach where direct selling is less practical.

Installed-base customers

Purchase disposables, service, and maintenance tied to existing IRADIMED equipment.

Strategia

IRADIMED is focused on growing its installed base in MRI-compatible devices while expanding recurring revenue from disposables, service, and maintenance. The company is also investing in capacity and product development, including a new facility and in-house manufacturing capability for certain components, to support growth and reduce supply dependence.

Grow installed base and recurring revenueKeskipitkä aikaväli

Recurring disposables and service improve revenue visibility and leverage the installed base.

Expand manufacturing capacityLyhyt aikaväli

The new facility is intended to accommodate growth and support operations at higher scale.

Reduce supplier concentrationKeskipitkä aikaväli

Single-sourced components create continuity risk, so internalizing key parts can improve resilience.

Drive product awareness and market share in MRI monitoringKeskipitkä aikaväli

The 3880 monitor competes against established brands, so adoption depends on workflow and differentiation.

Maantiede

The business is heavily U.S.-centric, with 84% of 2025 revenue generated in the United States and 16% from international markets. International sales are supported through distributors, while the company manufactures and stores products at a single facility in Florida, creating both operational focus and concentration risk.

Riskit

IRADIMED faces concentration risk from a limited product set, a single manufacturing site, and reliance on key suppliers for specialized components. It also operates in a regulated, competitive medical-device market where FDA approvals, trade restrictions, distributor execution, and long sales cycles can delay growth or pressure margins.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Single-site manufacturing and storage1Supply-chain dependence2Product concentration3Regulatory approval risk4Competitive pressure5International distributor dependence6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Single-site manufacturing and storageVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Manufacturing and inventory are concentrated in one Florida facility, increasing disruption risk from operational events.

    Kohdistuu: Production continuity

  2. Supply-chain dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Critical raw materials and parts are sourced from single suppliers, including Chinese and Taiwanese manufacturers.

    Kohdistuu: Components and subassemblies

  3. Product concentrationVaikutus: KorkeaTodennäköisyys: Matala

    A large share of revenue comes from a small number of MRI-compatible devices, so demand shifts can materially affect results.

    Kohdistuu: Devices and related disposables

  4. Regulatory approval riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Medical-device commercialization depends on FDA clearances and ongoing compliance, which can delay launches or require redesigns.

    Kohdistuu: New products and modifications

  5. Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Larger rivals have broader product lines, deeper resources, and established customer relationships.

    Kohdistuu: MRI-compatible monitoring and infusion systems

  6. International distributor dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Non-U.S. sales rely on third parties, which can weaken pricing control and execution quality.

    Kohdistuu: International revenue

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition by product type

Different timing applies to devices, disposables, maintenance amortization, and services, affecting quarterly revenue mix.

Vaikutus: Can shift revenue between periods and affect gross margin trends

Allowance for doubtful accounts

Domestic sales are generally made on open credit terms, requiring estimates for collectability.

Vaikutus: Affects operating income and receivables valuation

Inventory valuation

Specialized components and finished goods can become obsolete or require write-downs if demand changes.

Vaikutus: Can materially affect cost of revenue and gross profit

Long-lived asset and facility depreciation

The new facility and related equipment increase capitalized assets and future depreciation expense.

Vaikutus: Affects operating expense run-rate and asset carrying values

Income tax estimates and credits

Tax expense is influenced by state taxes, R&D credits, and changing tax law, including recent U.S. tax changes.

Vaikutus: Can move effective tax rate and net income

Seasonality

Third-quarter bookings are historically lower due to summer seasonality, affecting comparability across quarters.

Vaikutus: Can create uneven revenue and order trends

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026